Recent advances in schistosomiasis

Current Infectious Disease Reports

Volumn 3, Issue 1, 2001, Pages 59-67

  Olds, G Richard ^a   Dasarathy, Srinivasan ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Artemether; Praziquantel; Schistosoma; Schistosoma Mansoni; Schistosomiasis

Indexed keywords

EID: 0038200084     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-001-0060-1     Document Type: Article

References (50)

1. Elliott DG: Schistosomiasis. Pathophysiology, diagnosis and treatment. Gastroenterol Clin North Am 1996, 25:599–625.
2. Jourdane JG, Théron A: Larval development: eggs to cercariae. In The Biology of Schistosomes from Genes to Latrines. Edited by Rollinson D, Simpson AJG. London: Academic Press; 1987:83–113.
3. Jacobs W, Deelder A, Van Marck C: Schistosomal granuloma modulation: II. Specific immunogenic carbohydrates can modulate egg antigen induced hepatic granuloma formation. Parasitol Res 1999, 85:14–18.
4. Olds GR, Stavitsky AB: Mechanisms of in vivo modulation of granulomatous inflammation in murine schistosomiasis japonica. Infect Immun 1986, 52:513–518.
5. Bergquist RN, Colley DG: Schistosomiasis vaccines: research to development. Parasitol Today 1998, 14:99–104. The authors present a classic and objective review of the recent advances in the approach to vaccine development.
6. Wiest PM, Wu G, Zhong S, et al.: Impact of annual screening and chemotherapy with praziquantel on Schistosomiasis japonica on Jishan Island, People’s Republic of China. Am J Trop Med Hyg 1994, 51:162–169.
7. Olds GR, Olveda R, Wu G, et al.: Immunity and morbidity in Schistosoma japonicum infection. Am J Trop Med Hyg 1996, 55:121–126.
8. Nokes C, McGarvey ST, Shiue L, et al.: Evidence for an improvement in cognitive function following treatment of Schistosoma japonicum infection in Chinese primary school children. Am J Trop Med Hyg 1999, 60:556–565. This paper specifically addresses a new issue of reversal of subtle morbidity in schistosomiasis, with therapy. Evidence suggests that this parasite infestation results in cognitive dysfunction in young children.
9. Wiest PM, Wu G, Zhong S, et al.: Morbidity due to schistosomiasis japonicum in the People’s Republic of China. Am J Trop Med Hyg 1992, 86:47–50.
10. McGarvey ST, Wu A, Zhang S, et al.: Child growth, nutritional status and schistosomiasis japonicum in Jiangxi, People’s Republic of China. Am J Trop Med Hyg 1993, 48:547–553.
11. McGarvey ST, Aligui G, Araham KK, et al.: Schistosomiasis japonica and childhood nutritional status in northeastern Leyte, The Philippines: a randomized trial of praziquantel versus placebo. Am J Trop Med Hyg 1996, 54:498–502.
12. Olds GR, King C, Hewlett J, et al.: Double-blind placebocontrolled study of concurrent administration of albendazole and praziquantel in school children with schistosomiasis and geohelminths. J Infect Dis 1999, 179:996–1003. This is the first study of its kind to prove the impact of chemotherapy on subtle morbidity, particularly anemia. It also comprehensively addresses the side effects of praziquantel.
13. Pearce GJ, Sher A: Mechanisms of immune evasion in schistosomiasis. Contrib Microbiol Immunol 1987, 8:219–232.
14. Parizade M, Arnon R, Lachmann PJ, et al.: Functional and antigenic similarities between a 94 kDa protein of Schistosoma mansoni (SCIP-1) and human CD 59. J Exp Med 1994, 17:1625–1636.
15. Duvaux-Miret O, Stefano GB, Smith EM, et al.: Immunosuppression in the definitive and intermediate hosts of the human parasite Schistosoma mansoni by release of immunoactive neuropeptides. Proc Natl Acad Sci USA 1992, 8:778–781.
16. Kaplan MH, Whitfield JR, Boros DL, Grusby MJ: Th2 cells are required for the Schistosoma mansoni egg induced granulomatous response. J Immunol 1998, 160:1850–1856.
17. Wynn TA, Morawetz R, Schartor-Kersten T, et al.: Analysis of granuloma formation in double cytokine deficient mice reveals a helper cell 2-type cytokine responses in vivo, J Immunol 1997, 159:5014–5023.
18. Yap G, Cheever AW, Caspar P, et al.: Unimpaired down modulation of the hepatic granulomatous response in CD8 T cell and γ interferon-deficient mice chronically infected with Schistosoma mansoni. Infect Immunol 1997, 65:2583–2586.
19. Jankovic D, Cheever AW, Kullberg MC, et al.: CD4 and T cell mediated granulomatous pathology in schistosomiasis is down regulated by a B cell dependant mechanism requiring Fc receptor signaling. J Exp Med 1998, 187:619–629.
20. Cheever AW, Yap AS: Immunological basis of disease and disease regulation in schistosomiasis. Chem Immunol 1997, 66:159–176.
21. Mountford AP, Shires VL, Anderson S: Interleukin 12 and protective immunity to schistosomes. Braz J Med Biol Res 1998, 31:163–169.
22. James SL: Experimental models of immunization against schistosomiasis: lessons for vaccine development. Immunol Invest 1992, 21:477–493.
23. Butterworth AG: Immunological aspects of schistosomiasis. Br Med Bull 1998, 54:357–368. This overview of the immunology of schistosomiasis addresses most of the current views about host immune mechanisms in schistosomiasis.
24. Olveda RM, Daniel BL, Ramirez BDL, et al.: Schistosomiasis japonica in the Philippines: the long-term impact of population-based chemotherapy on infection, transmission and morbidity. J Infect Dis 1996, 176:163–172.
25. Dean DA, Mangold BL, Harrison RA, Riciardone MD: Homologous and heterologous protective immunity to Egyptian strains of Schistosoma mansoni and S. haematobium induced by ultraviolet irradiated cercariae. Parasitol Immunol 1996, 18:403–410.
26. James SL, Pearce EJ: The influence of adjuvant on induction of protective immunity by a non living vaccine against schistosomiasis. J Immunol 1988, 140:2753–2759.
27. Dunne DW, Butterworth AG, Fulford AJC, et al.: Immunity after treatment of human schistosomiasis; association between IgE antibodies to adult worm antigens and resistance to reinfection. Eur J Immunol 1992, 22:1483–1494.
28. Remoue F, Rogerie F, Gallissot MC, et al.: Sex dependant neutralizing humoral response to Schistosoma mansoni 28 GST antigen in infected human populations. J Infect Dis 2000, 181:1855–1859.
29. Capron A: 1998 Schistosomiasis: forty years war on the worm. Parasitol Today 14:379–384. The amount of information this paper offers, especially in terms of still-current thoughts on this rapidly progressing field, makes it perhaps the best review of this interesting topic.
30. Engels D, Nahimana S, Gryseels B: Comparison of the direct fecal smear and two thick smear techniques for the diagnosis of intestinal parasitic infection. Trop Med Hyg 1996, 90:523–525.
31. Alves-Brito CF, Simpson AJ, Bahia-Oliveria LM, et al.: Analysis of anti-keyhole limpet hemocyanin antibody in Brazilians supports its use for the diagnosis of acute Schistosoma mansoni. Trans R Soc Trop Med Hyg 1992, 86:53–56.
32. Hassan MM, Hegab MH, Sohman SZ, et al.: Relationship between circulating antigen level and morbidity in Schistosoma mansoni-infected children evaluated by ultrasonography. Am J Trop Med Hyg 1999, 61:635–638.
33. Rehmert CM, Mishinda HM, Hatz CF, et al.: Quantititive assessment of eosinophiluria in Schistosoma haematobium infections: a new marker of infection and bladder morbidity. Am J Trop Med Hyg 2000, 62:19–28.
34. World Health Organization: Proposals for a practical guide to the standardized use of ultrasound in the assessment of pathological changes. Presented at: Meeting on ultrasonography in schistosomiasis, World Health Organization, October 1–4, 1990; Cairo, Egypt.
35. Olds GR, Dasarathy S: Schistosomiasis. Curr Treat Opt Infect Dis 2000, 2:88–99. This recent review addresses many recent advances that could not be covered in this article, and is a useful supplement to it.
36. Cioli D, Pica-Mattoccia L, Archer S: Antischistosomal drugs: past, present and future? Pharmacol ther 1995, 68:35–85.
37. Gryseels B: Epidemiology, immunology and chemotherapy of S. mansoni infections in a recently exposed community in Senegal. Trop Geogr Med 1994, 46:209–219.
38. Bennett JL, Day T, Feng TAO, et al.: The development of resistance to anthelminthics: a perspective with an emphasis on the antischistosomal drug praziquantel. Exp Parasitol 1997, 87:260–267.
39. Utzinger J, N’Goran EK, N’Dri A, et al.: Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial. Lancet 2000, 355:1320–1325. This recent, randomized study discusses a new drug for schistosomiasis that is potentially exciting, especially in the context of emerging resistance to praziquantel.
40. Salafsy B, Ramaswamy K, He YX, et al.: Development and evaluation of LIPODEET, a new long-acting formulation of N, N-diethyl-m-toluamide (DEET) for the prevention of schistosomiasis. Am J Trop Med Hyg 1999, 61:743–750.
41. Waine EJ, McManus DP: Schistosomiasis vaccine development. The current picture. Bioessays 1997, 19:435–443.
42. Dupre, Herv M, Schacht AM, et al.: Control of schistosomiasis pathology by combination of Sm28GST DNA immunization and praziquantel therapy. J Infect Dis 1999, 180:454–463. This study, from the Pasteur Institute in Paris, led to the first phase-I and phase-II trials of these agents in humans.
43. Hagan P, El Meleigy, Traore M. Schistosomiasis research: the end of the beginning. Parasitol Today 1998, 14:392–394.
44. Brito CF, Fonseca CT, Goes AM, et al.: Human IgG1 and IgG3 recognition of Schistosoma mansoni 14 kDa fatty acid binding recombinant protein. Parasite Immunol 2000, 22:41–48.
45. Argiro LL, Kohlstadt SS, Henri SS, et al.: Identification of a candidate vaccine peptide on the 37 kDa Schistosoma mansoni GAPDH. Vaccine 2000, 18:2039–2048.
46. Argiro L, Henri S, Dessein H, et al.: Induction of a protection against S. mansoni with a MAP containing epitopes of Sm37-GAPDH and SM10-DLC. Effect of coadsorption with GM-CSF on alum. Vaccine 2000, 3:18:2033–2038.
47. Ribeiro De Jesus A, Araujo I, Bacellar O, et al.: Human immune responses to Schistosoma mansoni vaccine candidate antigens. Infect Immun 2000, 68:2797–803. This elegant paper on the responses to vaccine candidates is essential for anyone interested in learning about vaccines against schistosomiasis.
48. Zhang Y, Taylor MG, Bickle QD: Schistosoma japonicum myosin: cloning, expression and vaccination studies with the homologue of the S. mansoni myosin fragment IrV-5. Parasite Immunol 1998, 20:583–594.
49. Chen H, Nara T, Zeng X, et al.: Vaccination of domestic pig with recombinant paramyosin against Schistosoma japonicum in China. Vaccine 2000, 18:2142–2146.
50. Hernandez MG, Hafalla JC, Acosta LP, et al.: Paramyosin is a major target of the human IgA response against Schistosoma japonicum. Parasite Immunol 1999, 21:641–647.